Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)
SEK 3.21
(2.56%)
SEK 3.21
(2.56%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 16.03 Million SEK | 306.1% |
| 2023 | 3.94 Million SEK | 152.43% |
| 2022 | 1.56 Million SEK | 240.0% |
| 2021 | 460 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.73 Million SEK | -60.25% |
| 2024 Q1 | 4.36 Million SEK | 247.57% |
| 2024 Q4 | 9.63 Million SEK | 3047.39% |
| 2024 Q3 | 306 Thousand SEK | -82.35% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q2 | 471 Thousand SEK | 0.0% |
| 2023 FY | 3.94 Million SEK | 152.43% |
| 2023 Q3 | 2.17 Million SEK | 361.57% |
| 2023 Q4 | 1.25 Million SEK | -42.27% |
| 2022 FY | 1.56 Million SEK | 240.0% |
| 2021 FY | 460 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AcuCort AB | 6.59 Million SEK | -143.219% |
| AlzeCure Pharma AB (publ) | -476 Thousand SEK | 3468.277% |
| BioGaia AB (publ) | 950.19 Million SEK | 98.313% |
| Enzymatica AB (publ) | 31.86 Million SEK | 49.681% |
| Enorama Pharma AB (publ) | -3.9 Million SEK | 510.997% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | -9000.00 SEK | 178244.444% |
| Moberg Pharma AB (publ) | -2.09 Million SEK | 863.84% |
| Nanexa AB (publ) | 59.15 Million SEK | 72.898% |
| ODI Pharma AB | -1.34 Million SEK | 1295.034% |
| Orexo AB (publ) | 549.9 Million SEK | 97.084% |
| Probi AB (publ) | 220.21 Million SEK | 92.719% |
| Swedencare AB (publ) | 164.8 Million SEK | 90.271% |
| Swedish Orphan Biovitrum AB (publ) | 14.05 Billion SEK | 99.886% |
| Toleranzia AB | -919 Thousand SEK | 1844.614% |
| Vivesto AB | -10.65 Million SEK | 250.46% |